Cardiac safety of bedaquiline: A systematic and critical analysis of the evidence

European Respiratory Journal

Volumn 50, Issue 5, 2017, Pages

  Pontali, Emanuele ^a   Sotgiu, Giovanni ^b   Tiberi, Simon ^c,d   D'Ambrosio, Lia ^e,f   Centis, Rosella ^e   Migliori, Giovanni B ^e  

^a GALLIERA HOSPITAL   (Italy)

^b UNIVERSITY OF SASSARI   (Italy)

^c ROYAL LONDON HOSPITAL   (United Kingdom)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^e WORLD HEALTH ORGANIZATION   (Switzerland)

^f Public Health Consulting Group SAGL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BEDAQUILINE; QUINOLINE DERIVATIVE; TUBERCULOSTATIC AGENT;

CARDIOVASCULAR RISK; DRUG EFFICACY; DRUG EXPOSURE; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; HEART ARRHYTHMIA; HEART DISEASE; HEART ELECTROPHYSIOLOGY; HEART INFARCTION; HUMAN; LUNG EDEMA; LUNG EMBOLISM; MULTIDRUG RESISTANT TUBERCULOSIS; PRIORITY JOURNAL; Q WAVE; QRS COMPLEX; QT PROLONGATION; REVIEW; T WAVE; TREATMENT DURATION; TREATMENT WITHDRAWAL; CHEMICALLY INDUCED; ELECTROCARDIOGRAPHY; LONG QT SYNDROME;

ANTITUBERCULAR AGENTS; DIARYLQUINOLINES; ELECTROCARDIOGRAPHY; HUMANS; LONG QT SYNDROME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 85034050759     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.01462-2017     Document Type: Review

References (56)

1. Diel R, Rutz S, Castell S, et al. Tuberculosis: cost of illness in Germany. Eur Respir J 2012; 40: 143-151.
2. Diel R, Vandeputte J, de Vries G, et al. Costs of tuberculosis disease in the European Union: a systematic analysis and cost calculation. Eur Respir J 2014; 43: 554-565.
3. Tadolini M, Garcia-Prats AJ, D'Ambrosio L, et al. Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively-drug resistant tuberculosis: early experiences and challenges. Eur Respir J 2016; 48: 938-943.
4. Pontali E, Sotgiu G, D'Ambrosio L, et al. Bedaquiline and MDR-TB: a systematic and critical analysis of the evidence. Eur Respir J 2016; 47: 394-402.
5. Pontali E, D'Ambrosio L, Centis R, et al. Multidrug-resistance tuberculosis and beyond: an updated analysis of the current evidence on bedaquiline. Eur Respir J 2017; 49: 1700146.
6. Borisov SE, Dheda K, Enwerem M, et al. Effectiveness and safety of bedaquiline-containing regimens in the treatment of multidrug and extensively drug-resistant tuberculosis: a multicentre study. Eur Respir J 2017; 49: 1700387.
7. Dalcolmo M, Gayoso R, Sotgiu G, et al. Effectiveness and safety of clofazimine within a standard multidrug-resistant tuberculosis regimen in Brazil: first nation-wide report on over 2,500 cases. Eur Respir J 2017; 49: 1602445.
8. Tadolini M, Lingtsang RD, Tiberi S, et al. First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline. Eur Respir J 2016; 48: 935-938.
9. Tadolini M, Lingtsang RD, Tiberi S, et al. Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid, and clofazimine. Eur Respir J 2016; 48: 1527-1529.
10. Migliori GB, Pontali E, Sotgiu G, et al. Combined use of delamanid and bedaquiline to treat multidrug-resistant and extensively drug-resistant tuberculosis: a systematic review. Int J Mol Sci 2017; 18: 341.
11. D'Ambrosio L, Centis R, Tiberi S, et al. Delamanid and bedaquiline to treat multidrug-resistant and extensively drug-resistant tuberculosis in children: a systematic review. J Thorac Dis 2017; 9: 2093-2101.
12. Tiberi S, Payen MC, Sotgiu G, et al. Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of multidrug and extensively drug-resistant tuberculosis. Eur Respir J 2016; 47: 1235-1243.
13. Tiberi S, Sotgiu G, D'Ambrosio L, et al. Comparison of effectiveness and safety of imipenem/clavulanate-versus meropenem/clavulanate-containing regimens in the treatment of multidrug and extensively drug-resistant tuberculosis. Eur Respir J 2016; 47: 1758-1766.
14. Tiberi S, Sotgiu G, D'Ambrosio L, et al. Effectiveness and safety of imipenem-clavulanate added to an optimized background regimen (OBR) versus OBR control regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis. Clin Infect Dis 2016; 62: 1188-1190.
15. Arbex MA, Bonini EH, Kawakame Pirolla G, et al. Effectiveness and safety of imipenem/clavulanate and linezolid to treat multidrug and extensively drug-resistant tuberculosis at a referral hospital in Brazil. Rev Port Pneumol 2016; 22: 337-341.
16. Tiberi S, D'Ambrosio L, De Lorenzo S, et al. Ertapenem in the treatment of multidrug-resistant tuberculosis: first clinical experience. Eur Respir J 2016; 1: 333-336.
17. Sotgiu G, Centis R, D'Ambrosio L, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J 2012; 40: 1430-1442.
18. Sotgiu G, Pontali E, Migliori GB. Linezolid to treat MDR-/XDR-tuberculosis: available evidence and future scenarios. Eur Respir J 2015; 1: 25-29.
19. Amankwa K, Krishnan SC, Tisdale JE. Torsades de pointes associated with fluoroquinolones: importance of concomitant risk factors. Clin Pharmacol Ther 2004; 75: 242-247.
20. Choudhri SH, Harris L, Butany JW, et al. Clofazimine induced cardiotoxicity-A case report. Lepr Rev 1995; 66: 63-68.
21. Diacon AH, Pym A, Grobusch MP, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med 2014; 371: 723-732.
22. World Health Organization. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis. Interim policy guidance. WHO/HTM/TB/2013.6. Geneva, World Health Organization, 2013.
23. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for Industry. E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. Questions and Answers (R3). Guidance for Industry. June 2017 ICH, Revision 2. Available at: www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM073161.pdf. Date last accessed: July 14, 2017.
24. European Medicines Agency. ICH guideline E14: the clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs (R3)-questions and answers. EMA/CHMP/ICH/310133/ 200825. London, United Kingdom, January 2016. Available at: www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500002878.pdf. Date last accessed: July 14, 2017.
25. Postema PG, Wilde AA. The measurement of the QT interval. Curr Cardiol Rev 2014; 10: 287-294.
26. Dessertenne F. La tachycardie ventriculaire à deux foyers opposes variables. Arch Mal Coeur Vaiss 1966; 59: 263-272.
27. Schwartz PJ, Woosley RL. Predicting the unpredictable: Drug-Induced QT Prolongation and Torsades de Pointes. J Am Coll Cardiol 2016; 67: 1639-1650.
28. Moss AJ, Schwartz PJ, Crampton RS, et al. The long QT syndrome: prospective longitudinal study of 328 families. Circulation 1991; 84: 1136-1144.
29. Sharma ND, Rosman HS, Padhi ID, et al. Torsades de pointes associated with intravenous haloperidol in critically ill patients. Am J Cardiol 1998; 81: 238-240.
30. Pratt CM, Singh SN, Al-Khalidi HR, et al. The efficacy of azimilide in the treatment of atrial fibrillation in the presence of left ventricular dysfunction: results from the Azimilide Postinfarct Survival Evaluation (ALIVE) trial. J Am Coll Cardiol 2004; 43: 1211-1216.
31. Redfern WS, Carlsson L, Davis AS, et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 2003; 58: 32-45.
32. Yoon HY, Jo KW, Nam GB, et al. Clinical significance of QT-prolonging drug use in patients with MDR-TB or NTM disease. Int J Tuberc Lung Dis 2017; 21: 996-1001.
33. Rustomjee R, Diacon AH, Allen J, et al. Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. Antimicrob Agents Chemother 2008; 52: 2831-2835.
34. Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009; 360: 2397-2405.
35. Dooley KE, Park JG, Swindells S, et al. Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267. J Acquir Immune Defic Syndr 2012; 59: 455-462.
36. Diacon AH, Dawson R, von Groote-Bidlingmaier F, et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet 2012; 380: 986-993.
37. Diacon AH, Donald PR, Pym A, et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother 2012; 56: 3271-3276.
38. Diacon AH, Dawson R, Von Groote-Bidlingmaier F, et al. Randomized dose-ranging study of the 14-day early bactericidal activity of bedaquiline (TMC207) in patients with sputum microscopy smear-positive pulmonary tuberculosis. Antimicrob Agents Chemother 2013; 57: 2199-2203.
39. Diacon AH, Pym A, Grobusch MP, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med 2014; 371: 723-732.
40. Tiberi S, De Lorenzo S, Centis R, et al. Bedaquiline in MDR/XDR-TB cases: first experience on compassionate use. Eur Respir J 2014; 43: 289-292.
41. van Halsema C, Humphreys S, Bonington A. Extensively drug-resistant tuberculosis: early access to bedaquiline for a UK patient. Eur Respir J 2014; 43: 292-294.
42. Chua AP, Hoo GS, Chee CB, et al. First use of bedaquiline in a patient with XDR-TB in Singapore. BMJ Case Rep 2015; 2015.
43. Guglielmetti L, Le Dû D, Jachym M, et al. Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort. Clin Infect Dis 2015; 60: 188-194.
44. Ndjeka N, Conradie F, Schnippel K, et al. Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis. Int J Tuberc Lung Dis 2015; 19: 979-985.
45. Diacon AH, Dawson R, von Groote-Bidlingmaier F, et al. Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline. Am J Respir Crit Care Med 2015; 191: 943-953.
46. Philley JV, Wallace RJ Jr, Benwill JL, et al. Preliminary results of bedaquiline as salvage therapy for patients with nontuberculous mycobacterial lung disease. Chest 2015; 148: 499-506.
47. Lewis JM, Hine P, Walker J, et al. First experience of effectiveness and safety of bedaquiline for 18 months within an optimised regimen for XDR-TB. Eur Respir J 2016; 47: 1581-1584.
48. Tadolini M, Lingtsang RD, Tiberi S, et al. Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine. Eur Respir J 2016; 48: 1527-1529.
49. Lachâtre M, Rioux C, Le Dû D, et al. Bedaquiline plus delamanid for XDR tuberculosis. Lancet Infect Dis 2016; 16: 294.
50. Pym AS, Diacon AH, Tang S-J, et al. Bedaquiline in the treatment of multidrug-and extensively drug-resistant tuberculosis. Eur Respir J 2016; 47: 564-574.
51. Henry B, Revest M, Dournon N, et al. Preliminary favorable outcome for medically and surgically managed extensively drug-resistant tuberculosis, France, 2009-2014. Emerging Infect Dis 2016; 22: 518-521.
52. Udwadia ZF, Ganatra S, Mullerpattan JB. Compassionate use of bedaquiline in highly drug-resistant tuberculosis patients in Mumbai, India. Eur Respir J 2017; 49: 1601699.
53. Guglielmetti L, Jaspard M, Le Dû D, et al. Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis. Eur Respir J 2017; 49: 1601799.
54. Borisov SE, Dheda K, Enwerem M, et al. Effectiveness and safety of bedaquiline-containing regimens in the treatment of multidrug and extensively drug-resistant tuberculosis: a multicentre study. Eur Respir J 2017; 49: 1700387.
55. Olaru ID, Heyckendorf J, Andres S, et al. Bedaquiline-based treatment regimen for multidrug-resistant tuberculosis. Eur Respir J 2017; 49: 1700742.
56. European Medicines Agency. Sirturo (bedaquiline). Available at: www.ema.europa.eu/ema/index.jsp?curl=pages/ medicines/human/medicines/002614/human-med-001730.jsp&mid=WC0b01ac058001d124